Skip to main content
NCBI home page
Biochemical Journal logoLink to Biochemical Journal
. 1994 Oct 15;303(Pt 2):583–590. doi: 10.1042/bj3030583

Different effects of mucosal, bovine lung and chemically modified heparin on selected biological properties of basic fibroblast growth factor.

D Coltrini 1, M Rusnati 1, G Zoppetti 1, P Oreste 1, G Grazioli 1, A Naggi 1, M Presta 1
PMCID: PMC1137367  PMID: 7980421

Abstract

Heparins from bovine mucosa and lung, and chemically modified heparins were assayed for their capacity to: (i) protect human recombinant basic fibroblast growth factor (bFGF) from tryptic cleavage; (ii) prevent 125I-bFGF binding to heparan sulphate proteoglycans present in the extracellular matrix and on the cell surface of fetal bovine aortic endothelial GM 7373 cell cultures; (iii) affect 125I-bFGF binding to high-affinity tyrosine kinase FGF receptors present on the cell membrane of GM 7373 cells; (iv) inhibit the mitogenic activity exerted by bFGF in the same cells. The results demonstrate that the potency shown by mucosal heparins in the different assays is a direct function of size, very-low-molecular-mass heparin (2.0 kDa) being significantly less effective on a molar basis than unfractionated heparin (13.6 kDa). Increased flexibility of the backbone structure, as observed in reduced/oxidized heparins of different size, does not affect the capacity of the polysaccharide to interact with bFGF. In contrast, selective 2-O-desulphation, but not 6-O-desulphation, drastically reduced the capacity of heparin to protect bFGF from proteolytic cleavage, to affect its interaction with low- and high-affinity sites, and to inhibit its mitogenic activity. Two preparations of bovine lung heparin, differing in molecular mass, were as effective as mucosal heparin in the bFGF-tryptic-digestion assay and the endothelial-cell proteoglycan-binding assay, but they were highly inefficient at inhibiting the capacity of bFGF to interact with its tyrosine kinase receptors. Bovine lung heparins were also less effective than mucosal heparin as bFGF antagonists in GM 7373-cell-proliferation assays. N-Desulphated/N-acetylated bovine lung heparin retained only a significant capacity to protect bFGF from tryptic cleavage. The results demonstrate that different chemical features of the heparin molecule, including decrease in molecular mass, selective desulphation, disaccharide composition and clustering, affect differently the capacity of the glycosaminoglycan to interact with bFGF and to influence its biological behaviour in different assays in vitro and in endothelial cell cultures. Our findings should aid the design of synthetic oligosaccharides aimed at improving the bioavailability of bFGF when administered in vivo as a therapeutic agent.

Full text

PDF
583

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson K. J., Dam D., Lee S., Cotman C. W. Basic fibroblast growth factor prevents death of lesioned cholinergic neurons in vivo. Nature. 1988 Mar 24;332(6162):360–361. doi: 10.1038/332360a0. [DOI] [PubMed] [Google Scholar]
  2. Ayotte L., Perlin A. S. N.m.r. spectroscopic observations related to the function of sulfate groups in heparin. Calcium binding vs. biological activity. Carbohydr Res. 1986 Jan 1;145(2):267–277. doi: 10.1016/s0008-6215(00)90434-8. [DOI] [PubMed] [Google Scholar]
  3. BITTER T., MUIR H. M. A modified uronic acid carbazole reaction. Anal Biochem. 1962 Oct;4:330–334. doi: 10.1016/0003-2697(62)90095-7. [DOI] [PubMed] [Google Scholar]
  4. Bashkin P., Doctrow S., Klagsbrun M., Svahn C. M., Folkman J., Vlodavsky I. Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules. Biochemistry. 1989 Feb 21;28(4):1737–1743. doi: 10.1021/bi00430a047. [DOI] [PubMed] [Google Scholar]
  5. Basilico C., Moscatelli D. The FGF family of growth factors and oncogenes. Adv Cancer Res. 1992;59:115–165. doi: 10.1016/s0065-230x(08)60305-x. [DOI] [PubMed] [Google Scholar]
  6. Casu B., Diamantini G., Fedeli G., Mantovani M., Oreste P., Pescador R., Porta R., Prino G., Torri G., Zoppetti G. Retention of antilipemic activity by periodate-oxidized non-anticoagulant heparins. Arzneimittelforschung. 1986 Apr;36(4):637–642. [PubMed] [Google Scholar]
  7. Casu B., Gennaro U. A conductimetric method for the determination of sulphate and carboxyl groups in heparin and other mucopolysaccharides. Carbohydr Res. 1975 Jan;39(1):168–176. doi: 10.1016/s0008-6215(00)82654-3. [DOI] [PubMed] [Google Scholar]
  8. Casu B. Heparin structure. Haemostasis. 1990;20 (Suppl 1):62–73. doi: 10.1159/000216162. [DOI] [PubMed] [Google Scholar]
  9. Casu B., Johnson E. A., Mantovani M., Mulloy B., Oreste P., Pescador R., Prino G., Torri G., Zoppetti G. Correlation between structure, fat-clearing and anticoagulant properties of heparins and heparan sulphates. Arzneimittelforschung. 1983;33(1):135–142. [PubMed] [Google Scholar]
  10. Casu B., Moretti M., Oreste P., Riva A., Torri G., Vercellotti J. R. Glycosaminoglycans from pig duodenum. Arzneimittelforschung. 1980;30(11):1889–1892. [PubMed] [Google Scholar]
  11. Casu B. Structure and biological activity of heparin. Adv Carbohydr Chem Biochem. 1985;43:51–134. doi: 10.1016/s0065-2318(08)60067-0. [DOI] [PubMed] [Google Scholar]
  12. Coltrini D., Rusnati M., Zoppetti G., Oreste P., Isacchi A., Caccia P., Bergonzoni L., Presta M. Biochemical bases of the interaction of human basic fibroblast growth factor with glycosaminoglycans. New insights from trypsin digestion studies. Eur J Biochem. 1993 May 15;214(1):51–58. doi: 10.1111/j.1432-1033.1993.tb17895.x. [DOI] [PubMed] [Google Scholar]
  13. Edelman E. R., Nugent M. A., Karnovsky M. J. Perivascular and intravenous administration of basic fibroblast growth factor: vascular and solid organ deposition. Proc Natl Acad Sci U S A. 1993 Feb 15;90(4):1513–1517. doi: 10.1073/pnas.90.4.1513. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Eriksson A. E., Cousens L. S., Weaver L. H., Matthews B. W. Three-dimensional structure of human basic fibroblast growth factor. Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3441–3445. doi: 10.1073/pnas.88.8.3441. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Flaumenhaft R., Moscatelli D., Rifkin D. B. Heparin and heparan sulfate increase the radius of diffusion and action of basic fibroblast growth factor. J Cell Biol. 1990 Oct;111(4):1651–1659. doi: 10.1083/jcb.111.4.1651. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Folkman J., Szabo S., Stovroff M., McNeil P., Li W., Shing Y. Duodenal ulcer. Discovery of a new mechanism and development of angiogenic therapy that accelerates healing. Ann Surg. 1991 Oct;214(4):414–427. doi: 10.1097/00000658-199110000-00006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Gigli M., Consonni A., Ghiselli G., Rizzo V., Naggi A., Torri G. Heparin binding to human plasma low-density lipoproteins: dependence on heparin sulfation degree and chain length. Biochemistry. 1992 Jul 7;31(26):5996–6003. doi: 10.1021/bi00141a006. [DOI] [PubMed] [Google Scholar]
  18. Gospodarowicz D., Cheng J. Heparin protects basic and acidic FGF from inactivation. J Cell Physiol. 1986 Sep;128(3):475–484. doi: 10.1002/jcp.1041280317. [DOI] [PubMed] [Google Scholar]
  19. Grinspan J. B., Mueller S. N., Levine E. M. Bovine endothelial cells transformed in vitro by benzo(a)pyrene. J Cell Physiol. 1983 Mar;114(3):328–338. doi: 10.1002/jcp.1041140312. [DOI] [PubMed] [Google Scholar]
  20. Guimond S., Maccarana M., Olwin B. B., Lindahl U., Rapraeger A. C. Activating and inhibitory heparin sequences for FGF-2 (basic FGF). Distinct requirements for FGF-1, FGF-2, and FGF-4. J Biol Chem. 1993 Nov 15;268(32):23906–23914. [PubMed] [Google Scholar]
  21. Habuchi H., Suzuki S., Saito T., Tamura T., Harada T., Yoshida K., Kimata K. Structure of a heparan sulphate oligosaccharide that binds to basic fibroblast growth factor. Biochem J. 1992 Aug 1;285(Pt 3):805–813. doi: 10.1042/bj2850805. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Imamura T., Mitsui Y. Heparan sulfate and heparin as a potentiator or a suppressor of growth of normal and transformed vascular endothelial cells. Exp Cell Res. 1987 Sep;172(1):92–100. doi: 10.1016/0014-4827(87)90096-6. [DOI] [PubMed] [Google Scholar]
  23. Inoue Y., Nagasawa K. Selective N-desulfation of heparin with dimethyl sulfoxide containing water or methanol. Carbohydr Res. 1976 Jan;46(1):87–95. doi: 10.1016/s0008-6215(00)83533-8. [DOI] [PubMed] [Google Scholar]
  24. Isacchi A., Statuto M., Chiesa R., Bergonzoni L., Rusnati M., Sarmientos P., Ragnotti G., Presta M. A six-amino acid deletion in basic fibroblast growth factor dissociates its mitogenic activity from its plasminogen activator-inducing capacity. Proc Natl Acad Sci U S A. 1991 Apr 1;88(7):2628–2632. doi: 10.1073/pnas.88.7.2628. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Ishihara M., Tyrrell D. J., Stauber G. B., Brown S., Cousens L. S., Stack R. J. Preparation of affinity-fractionated, heparin-derived oligosaccharides and their effects on selected biological activities mediated by basic fibroblast growth factor. J Biol Chem. 1993 Mar 5;268(7):4675–4683. [PubMed] [Google Scholar]
  26. Johnson D. E., Williams L. T. Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res. 1993;60:1–41. doi: 10.1016/s0065-230x(08)60821-0. [DOI] [PubMed] [Google Scholar]
  27. Kan M., Wang F., Xu J., Crabb J. W., Hou J., McKeehan W. L. An essential heparin-binding domain in the fibroblast growth factor receptor kinase. Science. 1993 Mar 26;259(5103):1918–1921. doi: 10.1126/science.8456318. [DOI] [PubMed] [Google Scholar]
  28. Klagsbrun M., Baird A. A dual receptor system is required for basic fibroblast growth factor activity. Cell. 1991 Oct 18;67(2):229–231. doi: 10.1016/0092-8674(91)90173-v. [DOI] [PubMed] [Google Scholar]
  29. Lindahl U., Bäckström G., Hök M., Thunberg L., Fransson L. A., Linker A. Structure of the antithrombin-binding site in heparin. Proc Natl Acad Sci U S A. 1979 Jul;76(7):3198–3202. doi: 10.1073/pnas.76.7.3198. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Lindner V., Majack R. A., Reidy M. A. Basic fibroblast growth factor stimulates endothelial regrowth and proliferation in denuded arteries. J Clin Invest. 1990 Jun;85(6):2004–2008. doi: 10.1172/JCI114665. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Lobb R. R. Clinical applications of heparin-binding growth factors. Eur J Clin Invest. 1988 Aug;18(4):321–336. doi: 10.1111/j.1365-2362.1988.tb01020.x. [DOI] [PubMed] [Google Scholar]
  32. Maccarana M., Casu B., Lindahl U. Minimal sequence in heparin/heparan sulfate required for binding of basic fibroblast growth factor. J Biol Chem. 1993 Nov 15;268(32):23898–23905. [PubMed] [Google Scholar]
  33. Moscatelli D. Basic fibroblast growth factor (bFGF) dissociates rapidly from heparan sulfates but slowly from receptors. Implications for mechanisms of bFGF release from pericellular matrix. J Biol Chem. 1992 Dec 25;267(36):25803–25809. [PubMed] [Google Scholar]
  34. Moscatelli D. High and low affinity binding sites for basic fibroblast growth factor on cultured cells: absence of a role for low affinity binding in the stimulation of plasminogen activator production by bovine capillary endothelial cells. J Cell Physiol. 1987 Apr;131(1):123–130. doi: 10.1002/jcp.1041310118. [DOI] [PubMed] [Google Scholar]
  35. Nagasawa K., Inoue Y., Kamata T. Solvolytic desulfation of glycosaminoglycuronan sulfates with dimethyl sulfoxide containing water or methanol. Carbohydr Res. 1977 Sep;58(1):47–55. doi: 10.1016/s0008-6215(00)83402-3. [DOI] [PubMed] [Google Scholar]
  36. Nakayama Y., Iwahana M., Sakamoto N., Tanaka N. G., Osada Y. Inhibitory effects of a bacteria-derived sulfated polysaccharide against basic fibroblast growth factor-induced endothelial cell growth and chemotaxis. J Cell Physiol. 1993 Jan;154(1):1–6. doi: 10.1002/jcp.1041540102. [DOI] [PubMed] [Google Scholar]
  37. Neufeld G., Gospodarowicz D. The identification and partial characterization of the fibroblast growth factor receptor of baby hamster kidney cells. J Biol Chem. 1985 Nov 5;260(25):13860–13868. [PubMed] [Google Scholar]
  38. Presta M., Maier J. A., Ragnotti G. The mitogenic signaling pathway but not the plasminogen activator-inducing pathway of basic fibroblast growth factor is mediated through protein kinase C in fetal bovine aortic endothelial cells. J Cell Biol. 1989 Oct;109(4 Pt 1):1877–1884. doi: 10.1083/jcb.109.4.1877. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Rapraeger A. C., Krufka A., Olwin B. B. Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. Science. 1991 Jun 21;252(5013):1705–1708. doi: 10.1126/science.1646484. [DOI] [PubMed] [Google Scholar]
  40. Rosengart T. K., Kupferschmid J. P., Ferrans V. J., Casscells W., Maciag T., Clark R. E. Heparin-binding growth factor-I (endothelial cell growth factor) binds to endothelium in vivo. J Vasc Surg. 1988 Feb;7(2):311–317. [PubMed] [Google Scholar]
  41. Rusnati M., Urbinati C., Presta M. Internalization of basic fibroblast growth factor (bFGF) in cultured endothelial cells: role of the low affinity heparin-like bFGF receptors. J Cell Physiol. 1993 Jan;154(1):152–161. doi: 10.1002/jcp.1041540119. [DOI] [PubMed] [Google Scholar]
  42. Saksela O., Moscatelli D., Sommer A., Rifkin D. B. Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation. J Cell Biol. 1988 Aug;107(2):743–751. doi: 10.1083/jcb.107.2.743. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Sommer A., Rifkin D. B. Interaction of heparin with human basic fibroblast growth factor: protection of the angiogenic protein from proteolytic degradation by a glycosaminoglycan. J Cell Physiol. 1989 Jan;138(1):215–220. doi: 10.1002/jcp.1041380129. [DOI] [PubMed] [Google Scholar]
  44. Tsuboi R., Rifkin D. B. Recombinant basic fibroblast growth factor stimulates wound healing in healing-impaired db/db mice. J Exp Med. 1990 Jul 1;172(1):245–251. doi: 10.1084/jem.172.1.245. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Turnbull J. E., Fernig D. G., Ke Y., Wilkinson M. C., Gallagher J. T. Identification of the basic fibroblast growth factor binding sequence in fibroblast heparan sulfate. J Biol Chem. 1992 May 25;267(15):10337–10341. [PubMed] [Google Scholar]
  46. Tyrrell D. J., Ishihara M., Rao N., Horne A., Kiefer M. C., Stauber G. B., Lam L. H., Stack R. J. Structure and biological activities of a heparin-derived hexasaccharide with high affinity for basic fibroblast growth factor. J Biol Chem. 1993 Mar 5;268(7):4684–4689. [PubMed] [Google Scholar]
  47. Yanagisawa-Miwa A., Uchida Y., Nakamura F., Tomaru T., Kido H., Kamijo T., Sugimoto T., Kaji K., Utsuyama M., Kurashima C. Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science. 1992 Sep 4;257(5075):1401–1403. doi: 10.1126/science.1382313. [DOI] [PubMed] [Google Scholar]
  48. Yayon A., Klagsbrun M., Esko J. D., Leder P., Ornitz D. M. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell. 1991 Feb 22;64(4):841–848. doi: 10.1016/0092-8674(91)90512-w. [DOI] [PubMed] [Google Scholar]
  49. Zhang J. D., Cousens L. S., Barr P. J., Sprang S. R. Three-dimensional structure of human basic fibroblast growth factor, a structural homolog of interleukin 1 beta. Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3446–3450. doi: 10.1073/pnas.88.8.3446. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Zhu X., Komiya H., Chirino A., Faham S., Fox G. M., Arakawa T., Hsu B. T., Rees D. C. Three-dimensional structures of acidic and basic fibroblast growth factors. Science. 1991 Jan 4;251(4989):90–93. doi: 10.1126/science.1702556. [DOI] [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES